Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit

埃默里-杜克-奥兰多-CDC (EmDOC) 临床试验单位

• 批准号: 9388316
• 负责人: Jeffrey Lennox
• 金额: $ 278.37万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9388316
• 关键词: AIDS prevention; Address; Adolescent; Adult; Affect; American; Antibiotic Resistance; Antibiotic Therapy; Area; Bacterial Drug Resistance; Botswana; Centers for Disease Control and Prevention (U.S.); Childhood; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Comorbidity; Complex; Development; Enrollment; Epidemic; HIV; HIV Infections; Health; Hepatitis; Immunology; Infection; International; Kenya; Methods; Minority; National Institute of Allergy and Infectious Disease; Population; Prevention strategy; Principal Investigator; Research; Research Priority; Site; Tanzania; Thailand; Therapeutic; Tuberculosis; United States; Universities; Vaccines; Viral hepatitis; Woman; clinical implementation; flexibility; human subject; improved; low and middle-income countries; microbicide; prevent; support network; treatment strategy; tuberculosis treatment

DESCRIPTION (provided by the applicant): Through this application Emory University, Duke University, the Orlando Immunology Center, and the Centers for Disease Control and Prevention (CDC) are proposing an integration of eight existing, highly productive HIV research sites. The administrative core of the Emory, Duke, Orlando, CDC Clinical Trials Unit (EmDOC CTU) will be located at Emory University. The CTU will be led by three Principal Investigators: Carlos del Rio, Jeffrey Lennox, and Mark J. Mulligan. The CTU will include four Southeastern US research sites (2 located in Atlanta, one in Durham, and one in Orlando) and four international research sites (Botswana, Kenya, Tanzania, and Thailand). All of these sites are currently performing complex clinical trials in areas of the United States and internationally that are hard hit by the HIV epidemic, as well as by the concomitant epidemics of TB and viral hepatitis, and have access to diverse heavily affected populations. The Specific Aims of the Project are: 1. To contribute scientific expertise and human subject enrollment into studies that address these six key research areas-Adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; Strategies to address HIV and HIV-associated infections in pediatric and maternal populations; Integrated HIV prevention strategies; Microbicide strategies to prevent HIV infection; Vaccines to prevent HIV infection; and Strategies to address antibacterial resistance. 2. To be a leading CTU for contributions of women, minorities and adolescents to support Network clinical trials, both domestically and in low and middle income countries. 3. To operate an efficient and flexible CTU that can respond rapidly to evolving research opportunities. 4. To participate in the development and implementation of the clinical research plans of all of the NIAID clinical research networks that are addressing the six priority research areas. RELEVANCE: The CTU, working with the clinical research networks, will contribute to the development of improved strategies for the treatment and potential cure of HIV infection, to the treatment of TB and viral hepatitis, to improved methods for the prevention of HIV, and to improved treatments for antibiotic resistant infections. This CTU will contribute to improving the health of both the American public and the international public.

描述（由申请人提供）：通过此申请，埃默里大学、杜克大学、奥兰多免疫学中心和疾病控制与预防中心（CDC）提议整合八个现有的、高效的艾滋病毒研究站点。行政核心的埃默里，杜克，奥兰多，CDC临床试验单位（EmDOC CTU）将位于埃默里大学。反恐组将由三位首席调查员领导：卡洛斯·德尔·b里约热内卢、杰弗里·伦诺克斯和马克·j·穆里根。CTU将包括美国东南部的4个研究地点（2个位于亚特兰大，1个位于达勒姆，1个位于奥兰多）和4个国际研究地点（博茨瓦纳、肯尼亚、坦桑尼亚和泰国）。所有这些地点目前都在美国和国际上进行复杂的临床试验